Leiomyosarcoma - Pipeline Review, H1 2015

Publisher Name :
Date: 22-Jan-2015
No. of pages: 86
Inquire Before Buying

Global Markets Direct's, ‘Leiomyosarcoma - Pipeline Review, H1 2015', provides an overview of the Leiomyosarcoma's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Leiomyosarcoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Leiomyosarcoma and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope


  • The report provides a snapshot of the global therapeutic landscape of Leiomyosarcoma

  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

  • The report reviews key players involved in the therapeutics development for Leiomyosarcoma and enlists all their major and minor projects

  • The report summarizes all the dormant and discontinued pipeline projects

  • A review of the Leiomyosarcoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

  • A detailed assessment of monotherapy and combination therapy pipeline projects

  • Coverage of the Leiomyosarcoma pipeline on the basis of target, MoA, route of administration and molecule type

  • Latest news and deals relating related to pipeline products


Reasons to Buy

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

  • Develop strategic initiatives by understanding the focus areas of leading companies

  • Identify and understand important and diverse types of therapeutics under development for Leiomyosarcoma

  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

  • Devise corrective measures for pipeline projects by understanding Leiomyosarcoma pipeline depth and focus of Indication therapeutics

  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Leiomyosarcoma - Pipeline Review, H1 2015

Table of Contents

Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Leiomyosarcoma Overview 6
Therapeutics Development 7
Pipeline Products for Leiomyosarcoma - Overview 7
Pipeline Products for Leiomyosarcoma - Comparative Analysis 8
Leiomyosarcoma - Therapeutics under Development by Companies 9
Leiomyosarcoma - Therapeutics under Investigation by Universities/Institutes 10
Leiomyosarcoma - Pipeline Products Glance 11
Late Stage Products 11
Clinical Stage Products 12
Early Stage Products 13
Leiomyosarcoma - Products under Development by Companies 14
Leiomyosarcoma - Products under Investigation by Universities/Institutes 15
Leiomyosarcoma - Companies Involved in Therapeutics Development 16
GlaxoSmithKline plc 16
Karyopharm Therapeutics, Inc. 17
Merck & Co., Inc. 18
Mirati Therapeutics Inc. 19
Novartis AG 20
Pharma Mar, S.A. 21
Leiomyosarcoma - Therapeutics Assessment 22
Assessment by Monotherapy Products 22
Assessment by Target 23
Assessment by Mechanism of Action 25
Assessment by Route of Administration 27
Assessment by Molecule Type 29
Drug Profiles 31
Cell Therapy 2 for Oncology and Infectious Disease - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
Cell Therapy to Target LMP-1 and LMP-2 for Oncology - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
Cell Therapy to Target LMP-1 and LMP-2 for Oncology and Infectious Diseases - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
everolimus - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
mocetinostat - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
NOV-110501 - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
pazopanib hydrochloride - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
pembrolizumab - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
selinexor - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
trabectedin - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
Leiomyosarcoma - Recent Pipeline Updates 60
Leiomyosarcoma - Dormant Projects 83
Leiomyosarcoma - Discontinued Products 84
Appendix 85
Methodology 85
Coverage 85
Secondary Research 85
Primary Research 85
Expert Panel Validation 85
Contact Us 86
Disclaimer 86

List of Tables

Number of Products under Development for Leiomyosarcoma, H1 2015 7
Number of Products under Development for Leiomyosarcoma - Comparative Analysis, H1 2015 8
Number of Products under Development by Companies, H1 2015 9
Number of Products under Investigation by Universities/Institutes, H1 2015 10
Comparative Analysis by Late Stage Development, H1 2015 11
Comparative Analysis by Clinical Stage Development, H1 2015 12
Comparative Analysis by Early Stage Development, H1 2015 13
Products under Development by Companies, H1 2015 14
Products under Investigation by Universities/Institutes, H1 2015 15
Leiomyosarcoma - Pipeline by GlaxoSmithKline plc, H1 2015 16
Leiomyosarcoma - Pipeline by Karyopharm Therapeutics, Inc., H1 2015 17
Leiomyosarcoma - Pipeline by Merck & Co., Inc., H1 2015 18
Leiomyosarcoma - Pipeline by Mirati Therapeutics Inc., H1 2015 19
Leiomyosarcoma - Pipeline by Novartis AG, H1 2015 20
Leiomyosarcoma - Pipeline by Pharma Mar, S.A., H1 2015 21
Assessment by Monotherapy Products, H1 2015 22
Number of Products by Stage and Target, H1 2015 24
Number of Products by Stage and Mechanism of Action, H1 2015 26
Number of Products by Stage and Route of Administration, H1 2015 28
Number of Products by Stage and Molecule Type, H1 2015 30
Leiomyosarcoma Therapeutics - Recent Pipeline Updates, H1 2015 60
Leiomyosarcoma - Dormant Projects, H1 2015 83
Leiomyosarcoma - Discontinued Products, H1 2015 84

List of Figures

Number of Products under Development for Leiomyosarcoma, H1 2015 7
Number of Products under Development for Leiomyosarcoma - Comparative Analysis, H1 2015 8
Number of Products under Development by Companies, H1 2015 9
Number of Products under Investigation by Universities/Institutes, H1 2015 10
Comparative Analysis by Clinical Stage Development, H1 2015 12
Assessment by Monotherapy Products, H1 2015 22
Number of Products by Top 10 Targets, H1 2015 23
Number of Products by Stage and Top 10 Targets, H1 2015 23
Number of Products by Top 10 Mechanism of Actions, H1 2015 25
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 25
Number of Products by Top 10 Routes of Administration, H1 2015 27
Number of Products by Stage and Top 10 Routes of Administration, H1 2015 28
Number of Products by Top 10 Molecule Types, H1 2015 29
Number of Products by Stage and Top 10 Molecule Types, H1 2015 30

  • Cyclophosphamide Market in US - Manufacturing and Consumption, Outlook and Forecast 2020-2026
    Published: 28-May-2020        Price: US 2700 Onwards        Pages: 93
    Cyclophosphamide (CP), also known as cytophosphane among other names, is a medication used as chemotherapy and to suppress the immune system. As chemotherapy it is used to treat lymphoma, multiple myeloma, leukemia, ovarian cancer, breast cancer, small cell lung cancer, neuroblastoma, and sarcoma. This report contains market size and forecasts of Cyclophosphamide in US, including the following market information: US Cyclophosphamide Market Revenue, 2015-2020, 2021-2026, ($ ......
  • Paclitaxel Market in US - Manufacturing and Consumption, Outlook and Forecast 2020-2026
    Published: 28-May-2020        Price: US 2700 Onwards        Pages: 102
    Paclitaxel is a mitotic inhibitor used in Cancer chemotherapy; Paclitaxel was discovered in 1962 as a result of a U.S. National Cancer Institute-funded screening program; Monroe Wall and Mansukh Wani isolated the drug from the bark of the Pacific yew, Taxus brevifolia, and named it "taxol". This report contains market size and forecasts of Paclitaxel in US, including the following market information: US Paclitaxel Market Revenue, 2015-2020, 2021-2026, ($ millions) US......
  • Docetaxel Market in US - Manufacturing and Consumption, Outlook and Forecast 2020-2026
    Published: 28-May-2020        Price: US 2700 Onwards        Pages: 90
    Docetaxel is a chemotherapy medication used to treat a number of types of Cancer. This includes breast Cancer, head and neck Cancer, stomach Cancer, Prostate Cancer and non-small-cell lung Cancer. It may be used by itself or along with other chemotherapy medication. It is given by slow injection into a vein. This report contains market size and forecasts of Docetaxel in US, including the following market information: US Docetaxel Market Revenue, 2015-2020, 2021-2026, ($ mil......
  • Global Cancer Treatment Drugs Market Research Report 2020 (Covid-19 Version)
    Published: 27-May-2020        Price: US 3500 Onwards        Pages: 167
    Summary Cancer Treatment Drugs are used to treat malignancies, or cancerous growths. Depending on the technology it cans classification into Chemotherapy, Targeted Therapy, Immunotherapy (Biologic Therapy), Hormonal Therapy and Others. Market Segment as follows: By Region - Asia-Pacific - North America - Europe - South America - Middle East & Africa By Type - Chemotherapy - Targeted Therapy......
  • 2015-2027 Global Breast Cancer Industry Market Research Report, Segment by Player, Type, Application, Marketing Channel, and Region
    Published: 26-May-2020        Price: US 2960 Onwards        Pages: 112
    The worldwide market for Breast Cancer is estimated to grow at a CAGR of roughly X.X% in the next 8 years, and will reach X.X million US$ in 2027, from X.X million US$ in 2020. The report covers market size status and forecast, value chain analysis, market segmentation of Top countries in Major Regions, such as North America, Europe, Asia-Pacific, Latin America and Middle East & Africa, by type, application and marketing channel. In addition, the report focuses on the driving fact......
  • COVID-19 Impact on Antibody-drug Conjugate Market, Global Research Reports 2020-2021
    Published: 26-May-2020        Price: US 3250 Onwards        Pages: 97
    This report covers market size and forecasts of Antibody-drug Conjugate, including the following market information: Global Antibody-drug Conjugate Market Size, 2019-2021, and 2020 (quarterly data), (US$ Million) & (K Units) Global Antibody-drug Conjugate Market Size by Type and by Application, 2019-2021, and 2020 (quarterly data), (US$ Million) & (K Units) Global Antibody-drug Conjugate Market Size by Region (and Key Countries), 2019-2021......
  • Global Hydroxycarbamide Market Research Report 2020 (Covid-19 Version)
    Published: 26-May-2020        Price: US 3500 Onwards        Pages: 109
    Summary Hydroxycarbamide, also known as hydroxyurea, is a medication used in sickle-cell disease, chronic myelogenous leukemia, cervical cancer, and polycythemia vera. In sickle-cell disease it decreases the number of attacks. It is taken by mouth. Market Segment as follows: By Region - Asia-Pacific - North America - Europe - South America - Middle East & Africa By Type - Capsule - Tablet ......
  • COVID-19 Impact on DNA Repair Drugs Market, Global Research Reports 2020-2021
    Published: 26-May-2020        Price: US 3250 Onwards        Pages: 105
    This report covers market size and forecasts of DNA Repair Drugs, including the following market information: Global DNA Repair Drugs Market Size, 2019-2021, and 2020 (quarterly data), (US$ Million) & (K Units) Global DNA Repair Drugs Market Size by Type and by Application, 2019-2021, and 2020 (quarterly data), (US$ Million) & (K Units) Global DNA Repair Drugs Market Size by Region (and Key Countries), 2019-2021, and 2020 (quarterly data),......
  • 2015-2027 Global Capecitabine Industry Market Research Report, Segment by Player, Type, Application, Marketing Channel, and Region
    Published: 26-May-2020        Price: US 2960 Onwards        Pages: 139
    The worldwide market for Capecitabine is estimated to grow at a CAGR of roughly X.X% in the next 8 years, and will reach X.X million US$ in 2027, from X.X million US$ in 2020. The report covers market size status and forecast, value chain analysis, market segmentation of Top countries in Major Regions, such as North America, Europe, Asia-Pacific, Latin America and Middle East & Africa, by type, application and marketing channel. In addition, the report focuses on the driving facto......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - [email protected] / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs